Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
OLFM4 was originally cloned from human myeloblasts and found to be selectively expressed in inflammed colonic epithelium. Additionally we are shipping Olfactomedin 4 Kits (31) and Olfactomedin 4 Proteins (13) and many more products for this protein.
Showing 10 out of 68 products:
Cow (Bovine) Polyclonal OLFM4 Primary Antibody for WB - ABIN2773982
Clark, Edwards, Peterson, Clifton, Thompson, Sasaki, Suzuki, Kikuchi, Watabe, Kawakami, Sugano, Elgar, Johnson: Fugu ESTs: new resources for transcription analysis and genome annotation. in Genome research 2003
Show all 2 references for ABIN2773982
Human Polyclonal OLFM4 Primary Antibody for ICC, IF - ABIN4341402
Dassen, Punyadeera, Delvoux, Schulkens, Marchetti, Kamps, Klomp, Dijcks, de Goeij, DHooghe, Kyama, Ederveen, Dunselman, Groothuis, Romano: Olfactomedin-4 regulation by estrogen in the human endometrium requires epidermal growth factor signaling. in The American journal of pathology 2010
Show all 2 references for ABIN4341402
OLFM4 is proved to as a functional target for miR (show MLXIP Antibodies)-590.
Olfactomedin 4 is a novel tumor marker for triple-negative breast cancer for predicting and prognosis.
OLFM4 is downregulated by miR (show MLXIP Antibodies)-486-5p, which contributes to ovarian cancer tumorigenesis. Conversely, estrogen receptor (show ESR1 Antibodies) signaling downregulates miR (show MLXIP Antibodies)-486-5p and upregulates OLFM4 expression, slowing the development and progression of ovarian cancer.
Data show that olfactomedin 4 (OLFM4) is highly expressed in proliferating benign epithelial cells and in some carcinoma cells.
olfactomedin 4 appears to play a critical role in regulating progression of prostate cancer, and has potential as a new biomarker for prostate cancer.
Study demonstrates that epigenetic silencing of OLFM4 enhances gastric cancer cell invasion via activation of FAK (show PTK2 Antibodies) signaling.
suppression of OLFM4 expression may be a promising strategy in the development of novel cancer therapeutic drugs
Patients with an OLFM4 gene expression level above -7.5 were 6 times more likely to develop severe disease, after correction for age at hospitalization and gestational age.
Using a human vaginal epithelial cell line, the expression of mucin (show SLC13A2 Antibodies) 5 subtype B and olfactomedin-4 were down-regulated in response to N9, suggesting these markers could apply to humans
findings suggest that OLFM4 is not only involved in early stages of gastric carcinogenesis but also a useful prognostic marker for advanced gastric cancer
OLFM4 may function as a tumor suppressor and an anti-metastatic gene during tumor progression
Olfm4 deletion can successfully enhance immune defense against S. aureus, but not A. fumigatus, in chronic granulomatous disease mice.
OLFM4 exerts considerable influence on the host defense against H. pylori infection acting through NOD1 (show NOD1 Antibodies) and NOD2 (show NOD2 Antibodies) mediated NF-kappaB (show NFKB1 Antibodies) activation and subsequent cytokines and chemokines production, which in turn inhibit host immune response.
This gene was originally cloned from human myeloblasts and found to be selectively expressed in inflammed colonic epithelium. This gene encodes a member of the olfactomedin family. The encoded protein is an antiapoptotic factor that promotes tumor growth and is an extracellular matrix glycoprotein that facilitates cell adhesion.
, G-CSF-stimulated clone 1 protein
, antiapoptotic protein GW112
, PU.1 difference product 4